Biosimilar Substitution Laws.
作者信息
Gabay Michael
机构信息
The University of Illinois at Chicago, USA.
出版信息
Hosp Pharm. 2017 Sep;52(8):544-545. doi: 10.1177/0018578717726995. Epub 2017 Aug 22.
Abstract
摘要
相似文献
1
Biosimilar Substitution Laws.生物类似药替换法。
Hosp Pharm. 2017 Sep;52(8):544-545. doi: 10.1177/0018578717726995. Epub 2017 Aug 22.
2
Pharmaco-legal considerations in the clinical use of decongestants.减充血剂临床应用中的药物法律考量
Pharmacotherapy. 1993 Nov-Dec;13(6 Pt 2):135S-142S; discussion 143S-146S.
3
Prescription drug product substitution decision support.处方药产品替代决策支持。
J Am Pharm Assoc (2003). 2007 May-Jun;47(3):328-38. doi: 10.1331/JAPhA.2007.07502.
4
The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.生物制品和生物类似药在美国日益重要的作用：来自美国药师协会生物制品和生物类似药利益相关者会议的观点
J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):e15-e27. doi: 10.1016/j.japh.2017.05.014. Epub 2017 Jul 6.
5
In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?在生物类似药市场，会有50种停用胰岛素的方法吗？
J Diabetes Sci Technol. 2016 Aug 22;10(5):1188-91. doi: 10.1177/1932296816629488. Print 2016 Sep.
6
Regulatory considerations in oncologic biosimilar drug development.肿瘤生物类似药研发中的监管考量
MAbs. 2015;7(4):653-61. doi: 10.1080/19420862.2015.1040973.
7
[Biosimilar medicines. Scientific and legal disputes].[生物类似药。科学与法律纠纷]
Farm Hosp. 2010 Mar;34 Suppl 1:29-44. doi: 10.1016/S1130-6343(10)70007-6.
8
Biosimilar switching and related medical liability.生物类似药转换及相关医疗责任。
J Forensic Leg Med. 2018 Apr;55:93-94. doi: 10.1016/j.jflm.2018.02.018. Epub 2018 Feb 17.
9
Administration of Biosimilar Insulin Analogs: Role of Devices.生物类似胰岛素类似物的给药：器械的作用。
Diabetes Technol Ther. 2017 Feb;19(2):79-84. doi: 10.1089/dia.2016.0263.
10
Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.风湿病学家对生物类似药处方的看法：基于法国网络调查的结果
BioDrugs. 2016 Dec;30(6):585-592. doi: 10.1007/s40259-016-0202-5.
引用本文的文献
1
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.高级从业者将肿瘤生物类似药疗法融入实践的实用策略精简版
J Adv Pract Oncol. 2022 May;13(4):417-439. doi: 10.6004/jadpro.2022.13.4.5. Epub 2022 Jun 21.
2
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review.是否有除调查和民意测验之外的关于生物药品自动替代的研究证据？一项系统性综述。
BioDrugs. 2021 Sep;35(5):547-561. doi: 10.1007/s40259-021-00493-8. Epub 2021 Aug 16.
3
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.2015-2018 年医疗保险和医疗补助人群中生物类似物非格司亭的使用和费用。
J Manag Care Spec Pharm. 2021 May;27(5):660-666. doi: 10.18553/jmcp.2021.27.5.660.
4
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.评估州政府对仿制药和可互换生物替代品的监管差异。
JAMA Intern Med. 2021 Jan 1;181(1):16-22. doi: 10.1001/jamainternmed.2020.3588.
本文引用的文献
1
Biosimilars: Rationale and current regulatory landscape.生物类似药：基本原理与当前监管格局
Semin Arthritis Rheum. 2016 Apr;45(5 Suppl):S1-10. doi: 10.1016/j.semarthrit.2016.01.001. Epub 2016 Jan 21.
Zotero 插件